COVID-19 mRNA vaccine(Cansino)

mRNA新型冠状病毒肺炎疫苗(康希诺)

Report date: 2026/05/13 09:17:27

Base Information

Drug NameCOVID-19 mRNA vaccine(Cansino)
Drug Alias Name新型冠状病毒 mRNA疫苗(康希诺)CS-2034
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTianjin Cansino Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesKangxinuo (Shanghai) Biotechnology Co LtdCanSino Biologics IncTianjin Cansino Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A